FDA warns some Tydemy birth control pills may not be effective, could result in unexpected pregnancy

FDA warns some Tydemy birth control pills may not be effective, could result in unexpected pregnancy


Signage is seen outside the U.S. Food and Drug Administration headquarters in White Oak, Maryland, Aug. 29, 2020.

Andrew Kelly | Reuters

The U.S. Food and Drug Administration has warned that some Tydemy birth control pills may not be effective, several days after the manufacturer recalled two batches of the medication that were distributed in the U.S.

The FDA said the pills in question could result in unexpected pregnancy. The agency has not received any reports of adverse events related to Tydemy so far.

related investing news

This little-known pharma stock can rally 50%, Citi says

CNBC Pro

The manufacturer, Lupin Pharmaceuticals, announced a voluntary recall of two batches of Tydemy on July 29. The pills in those batches were distributed in the U.S. between June 3, 2022, and May 31, 2023.

CNBC Health & Science

Read CNBC’s latest health coverage:

Lupin, in a statement last week, said it recalled the batches because pills in one batch tested low for ascorbic acid and “high for a known impurity.” The company said a significant reduction in ascorbic acid could affect the product’s effectiveness.

Lupin said it is notifying wholesalers, distributors, drug chains and supermarkets of the problem and is working to get the affected pills off store shelves. Any store, distributor or wholesaler that has the affected pills in stock should immediately stop distributing them, the company said.

The batches of Tydemy that may not be effective come from lot numbers L200183 and L201560.

Lupin advised patients to continue taking their medication and immediately consult with their doctor about an alternative form of contraception.



Source

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Health

Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses

The Hers website arranged on a laptop in New York, US, on Wednesday, Feb. 12, 2025. Gabby Jones | Bloomberg | Getty Images Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk‘s patent on its branded drugs Ozempic and Wegovy is set to expire in January. “Canada is […]

Read More
Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’
Health

Trump threatens to impose up to 200% tariff on pharmaceuticals ‘very soon’

U.S. President Donald Trump speaks next to Defense Secretary Pete Hegseth during a cabinet meeting at the White House in Washington, D.C., U.S., July 8, 2025. Kevin Lamarque | Reuters President Donald Trump on Tuesday threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. “very soon.”  “They’re going to be tariffs […]

Read More
Healthy Returns: Medicaid cuts in Trump’s megabill may affect some drugmakers more than others
Health

Healthy Returns: Medicaid cuts in Trump’s megabill may affect some drugmakers more than others

U.S. President Donald Trump presents a sweeping spending and tax legislation, known as the “One Big Beautiful Bill Act,” after he signed it, at the White House in Washington, D.C., U.S., July 4, 2025. Leah Millis | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care […]

Read More